ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 177 filers reported holding ARGENX SE in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,305,769 | +44.1% | 2,656 | +14.2% | 0.02% | +53.8% |
| Q2 2023 | $906,123 | +99.2% | 2,325 | +90.4% | 0.01% | +85.7% |
| Q1 2023 | $454,920 | -10.9% | 1,221 | -9.4% | 0.01% | -12.5% |
| Q4 2022 | $510,663 | +3.4% | 1,348 | -3.6% | 0.01% | -11.1% |
| Q3 2022 | $494,000 | -25.0% | 1,398 | -19.7% | 0.01% | -18.2% |
| Q2 2022 | $659,000 | +18.1% | 1,740 | -1.6% | 0.01% | +37.5% |
| Q1 2022 | $558,000 | +36.8% | 1,768 | +51.8% | 0.01% | +60.0% |
| Q4 2021 | $408,000 | +19.6% | 1,165 | +3.0% | 0.01% | 0.0% |
| Q3 2021 | $341,000 | -3.1% | 1,131 | -3.3% | 0.01% | 0.0% |
| Q2 2021 | $352,000 | +8.3% | 1,170 | -0.8% | 0.01% | 0.0% |
| Q1 2021 | $325,000 | -5.8% | 1,180 | +0.4% | 0.01% | -16.7% |
| Q4 2020 | $345,000 | -2.8% | 1,175 | -13.0% | 0.01% | -14.3% |
| Q3 2020 | $355,000 | +14.1% | 1,351 | -2.2% | 0.01% | +16.7% |
| Q2 2020 | $311,000 | +80.8% | 1,381 | +6.0% | 0.01% | +50.0% |
| Q1 2020 | $172,000 | +8.2% | 1,303 | +31.9% | 0.00% | +33.3% |
| Q4 2019 | $159,000 | – | 988 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SAL Trading, LLC | 36,100 | $17,747,843 | 24.88% |
| Artia Global Partners LP | 49,238 | $24,206,878 | 10.06% |
| Paradigm Biocapital Advisors LP | 261,443 | $128,533,222 | 8.72% |
| Darwin Global Management, Ltd. | 45,615 | $22,425,702 | 7.89% |
| Avoro Capital Advisors LLC | 1,000,000 | $491,630,000 | 7.67% |
| Bellevue Group AG | 911,530 | $448,135,494 | 7.22% |
| Eagle Health Investments LP | 64,400 | $31,660,972 | 6.98% |
| DCF Advisers, LLC | 22,000 | $10,815,860 | 5.89% |
| SAL Trading, LLC | 8,149 | $4,006,293 | 5.62% |
| RTW INVESTMENTS, LP | 507,195 | $249,352,278 | 5.26% |